510(k)

K243561: Nano-Check Influenza+COVID-19 Dual Test

FDA 510(k) · Nano-Ditech Corporation · decided Jun 17, 2025

Key facts

510(k) number K243561
Device name Nano-Check Influenza+COVID-19 Dual Test
Applicant Nano-Ditech Corporation
Product code SCA
Date received Nov 18, 2024
Decision date Jun 17, 2025
Decision Substantially equivalent (SESE)
Submission type Dual Track
Review panel Microbiology
Medical specialty Microbiology

At a glance

  • None MAUDE adverse event reports
  • None Recall events
  • 1–9 UDI device identifiers (GUDID)
  • None Predicate devices cited
  • None Later submissions citing this device
  • 10–99 510(k)s with this product code
  • Yes 510(k) summary on file
  • No 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications